Added to YB: 2025-12-30
Pitch date: 2025-12-29
BXN.AX [bullish]
BLS Pharmaceuticals Limited
+164.63%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan.
Market Cap
AUD 260.2M
Pitch Price
AUD 0.41
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.26
P/E
16.87
EV/Sales
3.46
Sector
Life Sciences Tools and Services
Category
growth
Show full summary:
The portfolio I am taking into 2026 - Bioxyne Limited
BXN.AX: GMP-certified B2B cannabis contract manufacturer (Foxconn model) in Australia/Germany/UK. No brand/marketing risk vs other cannabis stocks. FY26 guidance: 65-75M AUD revenue, 11.5-13.5M EBITDA (115-150% YoY growth). Trading 9x PE, 6-7x EV/EBITDA.
Read full article (1 min)